Summit Therapeutics's market cap is currently ―. The company's EPS TTM is $-1.538; its P/E ratio is -2.69; Summit Therapeutics is scheduled to report earnings on May 9, 2024, and the estimated EPS forecast is $-0.06. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22
Income Statement	-
Total Revenue	-	-	-	$ 584.00K	-
Gross Profit	-	-	-	$ 584.00K	$ 1.13M
EBIT	-	$ -18.55M	$ -12.20M	$ -537.15M	$ -20.30M
EBITDA	-	$ -16.76M	$ -14.63M	$ -536.78M	$ -19.70M
Net Income Common Stockholders	$ -1.08B	$ -21.27M	$ -14.72M	$ -542.38M	$ -19.23M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 186.24M	$ 198.94M	$ 215.01M	$ 241.93M	$ 648.61M
Total Assets	$ 202.95M	$ 218.48M	$ 237.37M	$ 254.49M	$ 664.17M
Total Debt	$ 106.10M	$ 106.66M	$ 107.26M	$ 104.18M	$ 518.76M
Net Debt	$ -80.14M	$ -92.29M	$ -107.75M	$ -137.75M	$ -129.84M
Total Liabilities	$ 125.26M	$ 119.10M	$ 117.77M	$ 121.42M	$ 537.51M
Stockholders Equity	$ 77.69M	$ 99.38M	$ 119.60M	$ 133.48M	$ 126.65M
Cash Flow	-
Free Cash Flow	-	$ -14.95M	$ -29.07M	$ -13.18M	$ 5.20M
Operating Cash Flow	$ -19.46M	$ -14.90M	$ -29.27M	$ -13.13M	$ 5.19M
Investing Cash Flow	$ 60.57M	$ -3.49M	$ 207.00K	$ -645.06M	$ 10.00K
Financing Cash Flow	$ 6.25M	$ 229.00K	$ -80.00K	$ 80.11M	$ 520.06M

Currency in USD

Summit Therapeutics Earnings and Revenue History

Income Statement >

Summit Therapeutics Debt to Assets

Balance Sheet >

Summit Therapeutics Cash Flow

Cash Flow >

Summit Therapeutics Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing